Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift

Shuge Wang; Anxiong Huang; Yufeng Gu; Jun Li; Lingli Huang; Xu Wang; Yanfei Tao; Zhenli Liu; Congming Wu; Zonghui Yuan; Haihong Hao

doi:10.3390/antibiotics11030403

Rational Use of Danofloxacin for Treatment of Mycoplasma gallisepticum in Chickens Based on the Clinical Breakpoint and Lung Microbiota Shift

Antibiotics (Basel). 2022 Mar 17;11(3):403. doi: 10.3390/antibiotics11030403.

Authors

Shuge Wang^{1

2

3}, Anxiong Huang^{1

2}, Yufeng Gu^{1

2}, Jun Li⁴, Lingli Huang^{1

2}, Xu Wang^{1

2}, Yanfei Tao^{1

2}, Zhenli Liu^{1

2}, Congming Wu³, Zonghui Yuan^{1

2}, Haihong Hao^{1

2}

Affiliations

¹ National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, China.
² MOA Laboratory for Risk Assessment of Quality and Safety of Livestock and Poultry Products, Wuhan 430070, China.
³ National Center for Veterinary Drug Safety Evaluation, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
⁴ Institute of Food Safety and Nutrition, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China.

Abstract

The study was to explore the rational use of danofloxacin against Mycoplasma gallisepticum (MG) based on its clinical breakpoint (CBP) and the effect on lung microbiota. The CBP was established according to epidemiological cutoff value (ECV/CO_WT), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (CO_PD) and clinical cutoff value (CO_CL). The ECV was determined by the micro-broth dilution method and analyzed by ECOFFinder software. The CO_PD was determined according to PK-PD modeling of danofloxacin in infected lung tissue with Monte Carlo analysis. The CO_CL was performed based on the relationship between the minimum inhibitory concentration (MIC) and the possibility of cure (POC) from clinical trials. The CBP in infected lung tissue was 1 μg/mL according to CLSI M37-A3 decision tree. The 16S ribosomal RNA (rRNA) sequencing results showed that the lung microbiota, especially the phyla Firmicutes and Proteobacteria had changed significantly along with the process of cure regimen (the 24 h dosing interval of 16.60 mg/kg b.w for three consecutive days). Our study suggested that the rational use of danofloxacin for the treatment of MG infections should consider the MIC and effect of antibiotics on the respiratory microbiota.

Keywords: Mycoplasma gallisepticum; PK–PD cutoff values; clinical breakpoint; clinical cutoff values; danofloxacin; epidemiological cutoff values; lung microbiota.

Abstract

Grants and funding